中文摘要：

我们回顾地与 de novo AML 在 152 个中国病人调查了尖锐 myeloid 白血病(AML ) 的预示的因素并且谁比 60 岁老在我们的医院的接受治疗。木头等级测试显示出那 6 个参数包括老年，更高白的血房间(白血球) 计数，喂奶脱氢酶(LDH ) 和骨头髓(BM ) 在诊断，相反的风险 cytogenetics，和非变异的 CEBPα 爆炸；为老 AML 病人是全面幸存(OS ) 的重要不利预示的因素(P  ； = ；0.0013， 0.0358， 0.0132， 0.0242， 0.0236 和 0.0130，分别地) 。而且，老年和更高的 LDH 是为没有恶化的幸存(RFS ) 的重要不利预言者(P  ； = ；0.0447 和 0.0470，分别地) 。Univariate 分析木头等级测试为 OS 揭示了类似的结果到那些，在诊断的仅仅更高的 LDH 是为 RFS 的一个重要不利预言者(P  ； = ；0.028， HR：1.979， 95%CI：1.075-3.644 ) 。在 multivariate 分析，我们为 OS 向独立预示的因素识别了 2 个趋势，包括在诊断的 BM 强风(P  ； = ；0.057， HR：1.676， 95%CI：0.984-2.854 ) 并且 CEBPα 的变化地位；（ P  ； = ；0.064， HR：4.173， 95%CI：0.918-18.966 ) 。我们的数据显示那老年，性和 hematologic 疾病的以前的历史导致了更低的完全的宽恕率(P  ； = ；0.012， 0.051 和 0.086，分别地) 。我们进一步为在更旧的 AML 病人预言到正式就职治疗的预后和反应开发了一个容易的得分系统。有更低的分数的病人显示出显著地更长的 OS 和 RFS (P  ； = ；0.0006 和 0.1001，分别地) 并且更高的 CR 率(P  ； = ；0.014 ) 。我们的研究被它的回顾的性质和结果从我们被未来的使随机化的临床的试用进一步要验证的学习需要限制。

英文摘要：

We retrospectively investigated the prognostic factors of acute myeloid leukemia（AML） in 152 Chinese patients with de novo AML who were older than 60 years of age and who received treatment at our hospital.Log-rank test showed that 6 parameters including older age,higher white blood cell（WBC） counts,lactate dehydrogenase（LDH）and bone marrow（BM） blasts at diagnosis,unfavorable risk cytogenetics,and non-mutated CEBPα were significant adverse prognostic factors of overall survival（OS） for elderly AML patients（P = 0.0013,0.0358,0.0132,0.0242,0.0236 and 0.0130,respectively）.Moreover,older age and higher LDH were significant adverse predictors for relapse-free survival（RFS）（P = 0.0447 and 0.0470,respectively）.Univariate analysis revealed similar results for OS to those of the log-rank test and only higher LDH at diagnosis was a significant adverse predictor for RFS（P = 0.028,HR：1.979,95%CI：1.075-3.644）.In multivariate analysis,we identified 2 trends towards independent prognostic factors for OS,including BM blasts at diagnosis（P = 0.057,HR：1.676,95%CI：0.984-2.854）and mutation status of CEBPα（P = 0.064,HR：4.173,95%CI：0.918-18.966）.Our data indicated that older age,gender and a previous history of hematologic diseases resulted in lower complete remission rate（P = 0.012,0.051 and 0.086,respectively）.We further developed an easy scoring system for predicting prognosis and response to induction therapy in older AML patients.Patients who had lower scores showed significantly longer OS and RFS（P = 0.0006 and 0.1001,respectively） and higher CR rate（P = 0.014）.Our research is limited by its retrospective nature and the results from our study need to be further validated by prospective randomized clinical trials.